A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)

Bucci Laser Vision Institute50 enrolled

Overview

Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Post Operative Anterior Chamber Inflammation (Flare)

Interventions

Ketorolac Tromethamine 0.45%

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must be 18 years of age or older * Scheduled for cataract surgery by phacoemulsification * Subject must be willing to comply with all study requirements and be willing to give informed consent Exclusion Criteria: * Any subject that has a history of uveitis or active iritis * Subject can have no previous intraocular surgery with the exception of refractive surgery. but not within 6 months * No ocular use of prostaglandins within 2 weeks of surgery * Use of oral, injectable or topical steroids,nonsteroidal anti-inflammatory drugs (NSAIDs) or immunosuppressants within 14 days prior to surgery * Contraindications to NSAIDs * Active ocular infection

Outcomes

Primary Outcomes

Anterior Chamber Inflammation (Flare)

Anterior chamber flare measured by assessing the number of inflammatory cells in the anterior chamber.

Time frame: Day 14 of treatment